Skip to main content
Premium Trial:

Request an Annual Quote

Proligo Inks Deal for RNAx RNAi Technology

NEW YORK, April 26 (GenomeWeb News) - Proligo has signed a deal under which it has gained access to RNAx's RNA interference technology for use in the functional validation of siRNA oligos and gene targets, the companies said today.

 

Proligo owns all information and inventions derived from its work with the RNAx technology.

 

Additional terms of the deal were not disclosed.

 

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more